Polypoid nodule scar after gastric endoscopic submucosal dissection: results from a multicenter study

Abstract

Background and study aims A post-endoscopic submucosal dissection (ESD) scar is expected to look homogeneous, however, some patients develop benign polypoid nodule scar (PNS). Incidence of PNS is unknown, yet these scars have direct clinical implications because they may render evaluation of post-ESD neoplastic recurrence difficult. Therefore, we reviewed the clinical experience of 5 ESD referral centers and evaluated their PNS incidence and clinical management.

Patients and methods This was a retrospective multicenter case series enrolling patients that underwent R0, curative gastric ESD from 2003 to 2015 in 5 academic centers. PNS was defined as ESD site nodularity with hyperplastic or regenerative tissue histology.

Results A total of 2275 patients underwent gastric ESD with endoscopy control and 28 patients (18 men/10 women) developed PNS for overall incidence of 1.2 %. Incidence of PNS ranged from 0.15 % to 11.4 % between centers. All patients that developed PNS had primary neoplastic lesions located in the distal stomach. Considering only lesions situated in the antrum (n = 912), incidence of PNS was 3.1 %. After mean follow-up of 43 months (range 6 – 192), no malignant recurrence in the PNS has been identified. In five patients (17.8 %) PNS disappeared after a mean of 18 months.

Conclusion PNS occurs exclusively after ESD in the distal stomach in approximately 3.1 % of patients. Although PNS appearance can be concerning, no malignant recurrence was observed after curative R0 resection. Therefore, PNS should be viewed as a benign alteration that does not require any type of intervention, other than endoscopic surveillance.

• References

• 1 Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy Guideline. Endoscopy 2015; 47: 829-548
• 2 Ono H, Yao K, Fujishiro M. et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Dig Endosc 2016; 28: 3-15
• 3 Arantes V, Uedo N, Pedrosa MS. Polypoid nodular scar after endoscopic submucosal dissection in the gastric antrum. Rev Gastroenterol Mex 2017; 82: 267-269
• 4 Arantes V, Uedo N, Pedrosa MS. et al. Clinical relevance of aberrant polypoid nodule scar after endoscopic submucosal dissection. World J Gastrointest Endosc 09/2016; 16: 628-634
• 5 Piñeros EAF, Arantes V, Toyonaga T. Endoscopic submucosal dissection of early gastric cancer: State of the art. Rev Col Gastroenterol 2012; 27: 194-214
• 6 Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd. English edition. Gastric Cancer 2011; 14: 101-112
• 7 Yamamoto H. Endoscopic submucosal dissection – current success and future directions. Nat Rev Gastroenterol Hepatol 2012; 9: 519-529
• 8 Ito S, Kishi S, Ishikawa K. et al. A case of gastric ulcer scar with type IIa-like elevation in center of the lesion. Gastroenterol. Endosc 1974; 16: 194-197
• 9 Ito S, Ishikawa I, Kishi S. et al. Elevated type gastric ulcer scar. Gastroenterol. Endosc 1976; 18: 420-427
• 10 Kato H, Hattori K, Nishikawa H. et al. Endoscopic study on healing of gastric ulcer by the treatment with H2-blocker. Gastroenterol Endosc 1986; 28: 2291-2296
• 11 Nakamura T, Tsukamoto Y, Yamanaka T. et al. A study on the whitish protrusion appearing in the base of peptic ulcer during the administration of proton pump inhibitor. Gastroenterol Endosc 1992; 34: 1548-1554
• 12 Ashida K, Osaka N, Tei H. et al. Studies on the mechanism of the protrusion of the base of the ulcer during the administration of omeprazole. Gastroenterol Endosc 1989; 31: 1776-1782
• 13 Tanaka T, Kimura M, Akiyama T. et al. Long follow-up study of elevated scar of acute antral kissing ulcers. Gastroenterol Endosc 1984; 26: 1534-1537
• 14 Uedo N, Takeuchi Y, Yamada T. et al. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: A prospective randomized controlled trial. Am J Gastroenterol 2007; 102: 1610-1616
• 15 Okazaki M, Shimizu I, Ishikawa M. et al. Gastric mucosal levels of prostaglandins and leukotrienes in patients with gastric ulcer after treatment with rabeprazole in comparison to treatment with ranitidine. J Med Invest 02/2007; 54: 83-90
• 16 Wallace JL, Devchand PR. Emerging roles for cyclooxygenase-2 in the gastrointestinal mucosal defense. Br J Pharmacol 2005; 145: 275-282
• 17 Brzozowski T, Konturek PC, Konturek SJ. et al. Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor. J Physiol Pharmacol 2000; 51: 751-773
• 18 Sakai Y, Fujita K, Sakai H. et al. Prostaglandin E2 regulates the expression of basic fibroblast growth factor messenger RNA in normal human fibroblasts. Kobe J Med Sci 2001; 47: 35-45